LEEDS, England, June 3, 2019 /PRNewswire/ -- 4D pharma plc (AIM:
DDDD), a pharmaceutical company leading the development of Live
Biotherapeutics, today announces the presentation of a poster
detailing its Phase I/II clinical study of MRx0518 combined with
KEYTRUDA® in patients with solid tumours who have
failed prior anti-PD-1 therapy at the 55th Annual
Meeting of the American Society of Clinical Oncology (ASCO) in
Chicago, USA. ASCO is the
world's largest conference in the field of clinical oncology and
attracts approximately 39,000 oncology professionals from around
the world to discuss state-of-the-art treatment modalities, new
therapies, and ongoing controversies in the field.
The poster describes the proposed mechanism of action of MRx0518
and preclinical data in addition to details about the Phase I/II
study which is currently enrolling patients. This clinical study is
taking place at The University of Texas
MD Anderson Cancer Center and is part of 4D's clinical
collaboration with Merck & Co., Inc., (known as MSD outside
the United States and Canada). The poster was presented on Saturday
1 June during the session, "Developmental Immunotherapy and Tumor
Immunobiology" (poster number TPS2670). The lead author of the
poster was Shubham Pant, M.D., MD Anderson Cancer Center, Texas.
Alex Stevenson, 4D's Chief
Scientific Officer, commented: "We are pleased to have presented
this poster at such a prestigious oncology meeting."
A copy of the poster can be viewed at
https://www.4dpharmaplc.com/en/newsroom/posters-and-publications.
About 4D
Founded in February 2014, 4D is a
world leader in the development of Live Biotherapeutics, a novel
and emerging class of drugs, defined by the FDA as biological
products that contain a live organism, such as a bacterium, that is
applicable to the prevention, treatment or cure of a disease. 4D
has developed a proprietary platform that rationally identifies
novel bacteria based on a deep understanding of function and
mechanism. 4D's Live Biotherapeutic products are orally delivered
single strains of bacteria that are naturally found in the healthy
human gut. 4D has three clinical studies in progress, namely a
Phase II clinical study of Blautix® in Irritable
Bowel Syndrome, a Phase I/II study of MRx0518 in combination with
KEYTRUDA® (pembrolizumab) in solid tumours and a
Phase I study of MRx0518 in a neoadjuvant setting for patients with
solid tumours. Other focus programmes include disease areas such as
asthma and CNS disease.
About Cancer
Cancer is a group of diseases involving abnormal cell growth
with the potential to invade or spread to other parts of the body.
Globally, it is estimated that there were around 18 million new
cases in 2018 and that almost 10 million people died of cancer,
making it the leading cause of death world-wide. The number of
new cancer cases per year is expected to rise to 23.6 million by
2030. The global market for oncology drugs is expected to reach
$111.9bn by 2020.
The microbiome has been implicated in cancer treatment and
response in a range of clinical settings including standard
chemotherapy. The microbiome profile of patients has been
demonstrated to drive response to anti-PD-1 therapy in both
melanoma and non-small cell lung cancer.
About MRx0518
As both a monotherapy and in combination settings MRx0518 has
demonstrated robust efficacy as an immuno-stimulant and anti-tumour
agent in multiple tumour models such as breast cancer, renal cell
carcinoma and lung cancer. MRx0518 acts on both the innate and
adaptive immune system to induce a response mediated by TLR-5.
The Company is investigating MRx0518 across a range of clinical
cancer settings in 2019. In collaboration with Merck, Sharpe &
Dohme (Merck & Co. Inc), MRx0518 is being evaluated in an
open label Phase I/II study of MRx0518 in combination with
KEYTRUDA® (pembrolizumab) in patients with solid tumours
who have failed prior anti-PD-1 therapy. A Phase I randomised,
placebo-controlled study of MRx0518 as a monotherapy in a
neoadjuvant setting for solid tumours has also commenced.
For more information, refer to https://www.4dpharmaplc.com/.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
For further information please contact:
Duncan Peyton
Chief Executive
Officer
+44-(0)113-895-0130
Fay Weston
Head of Investor
Relations
+44-(0)7990-381713